Tonix Pharmaceuticals reports Q3 2026 TONMYA net sales of about $15 million
FROM THE WIRE · FINANCE.YAHOO.COM
Tonix Pharmaceuticals Holding Corp. Third quarter TONMYA® net sales of approximately $15 million, up 37% from the second quarter Approximately $163 million in cash and cash equivalents as of September 30, 2026 Strategic focus on supporting TONMYA growth and advancing core…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishStrong TONMYA sales growth and about $163 million in cash support the commercial story.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01TONMYA net sales rose 37% from the second quarter.
- 02Cash and equivalents were about $163 million as of September 30, 2026.
- 03The company is focused on TONMYA growth and core clinical programs.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets